Tryptyr
(Acoltremon)PreclinicalSmall molecule
This eye drop medication is used to treat dry eye disease by stimulating the eyes to produce more tears, helping to restore adequate moisture to the eyes.[1] Tryptyr is currently being investigated across 1 indication[3], with its most advanced program in Preclinical.[1]
Tryptyr is one of 37 small molecule programs targeting Eye Disease. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
36
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
5
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Neoral
NovartisPhase 3
Alphagan
AbbViePhase 3
Chantix
PfizerPhase 3
Bayer Aspirin
BayerPhase 3
Zovirax
BBp Consulting, Inc
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
CF101
CCan-Fite BioPharma
Phase 3
Carboxymethylcellulose
AbbViePhase 3
Refresh Plus
AbbViePhase 3
Cenegermin
DDompé Farmaceutici S.p.A
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
May 28, 2025
TRYPTYR
NDA NDA217370
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acoltremon. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]